Market Cap : 7.43 B | Enterprise Value : 6.38 B | PE Ratio : | PB Ratio : 8.76 |
---|
NAS:IONS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:IONS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ionis Pharmaceuticals's Enterprise Value is $6,381.9 Mil. Ionis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $-125.0 Mil. Therefore, Ionis Pharmaceuticals's EV-to-EBIT for today is -51.04.
During the past 13 years, the highest EV-to-EBIT of Ionis Pharmaceuticals was 807.90. The lowest was -699.20. And the median was -13.65.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ionis Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2020 was $6,860.4 Mil. Ionis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was $-125.0 Mil. Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 was -1.82%.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Ionis Pharmaceuticals's EV-to-EBIT falls into.
Ionis Pharmaceuticals's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 6381.908 | / | -125.043 | |
= | -51.04 |
Ionis Pharmaceuticals's current Enterprise Value is $6,381.9 Mil.
Ionis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was -50.747 (Mar. 2020 ) + -33.035 (Jun. 2020 ) + -29.122 (Sep. 2020 ) + -12.139 (Dec. 2020 ) = $-125.0 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2020 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2020 ) |
= | -125.043 | / | 6860.36778 | |
= | -1.82 % |
Ionis Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2020 was $6,860.4 Mil.
Ionis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 was -50.747 (Mar. 2020 ) + -33.035 (Jun. 2020 ) + -29.122 (Sep. 2020 ) + -12.139 (Dec. 2020 ) = $-125.0 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
No Headline